Tricyclic Pyrazole-Based Compounds as Useful Scaffolds for Cannabinoid CB1/CB2 Receptor Interaction

The therapeutic potential of second and third generation CB1R antagonists

(2020) Resat Cinar et al.   PHARMACOLOGY & THERAPEUTICS

Ketamine-induced antidepressant like effects in mice: A possible involvement of cannabinoid system

(2019) Fatemeh Khakpai et al.   BIOMEDICINE & PHARMACOTHERAPY

Development of Oxygen-Bridged Pyrazole-Based Structures as Cannabinoid Receptor 1 Ligands

(2019) Gabriele Murineddu et al.   MOLECULES

Overcoming the psychiatric side effects of the cannabinoid CB1 receptor antagonists: Current approaches for therapeutics development

(2019) Thuy Nguyen et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Novel pharmacological actions of Trequinsin Hydrochloride improve human sperm cell motility and function

(2019) R.C. McBrinn et al.   BRITISH JOURNAL OF PHARMACOLOGY

Heterogeneity of cannabinoid ligand-induced modulations in intracellular Ca2+ signals of mouse pancreatic acinar cells in vitro

(2018) Kun-kun Xia et al.   ACTA PHARMACOLOGICA SINICA

Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system

(2018) Maria S. Aymerich et al.   BIOCHEMICAL PHARMACOLOGY

The Role of Endogenous Neuroprotective Mechanisms in the Prevention of Retinal Ganglion Cells Degeneration

(2018) Marita Pietrucha-Dutczak et al.   Frontiers in Neuroscience

Metabolic side effects induced by olanzapine treatment are neutralized by CB1 receptor antagonist compounds co-administration in female rats

(2017) P. Lazzari et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Emerging therapeutic targets in cancer induced bone disease: A focus on the peripheral type 2 cannabinoid receptor

(2017) Silvia Marino et al.   PHARMACOLOGICAL RESEARCH

Cannabinoid CB2 receptor ligand profiling reveals biased signalling and off-target activity

(2017) Marjolein Soethoudt et al.   Nature Communications

Synthesis, molecular modeling and SAR study of novel pyrazolo[5,1- f ][1,6]naphthyridines as CB 2 receptor antagonists/inverse agonists

(2016) Antonio Dore et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Cannabinoids for treatment of glaucoma

(2016) Gary D. Novack   CURRENT OPINION IN OPHTHALMOLOGY

Tricyclic pyrazoles. Part 8. Synthesis, biological evaluation and modelling of tricyclic pyrazole carboxamides as potential CB 2 receptor ligands with antagonist/inverse agonist properties

(2016) Valeria Deiana et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

A critical review of both the synthesis approach and the receptor profile of the 8-chloro-1-(2′,4′-dichlorophenyl)- N -piperidin-1-yl-1,4,5,6-tetrahydrobenzo[6,7]cyclohepta[1,2- c ]pyrazole-3-carboxamide and analogue derivatives

(2016) Paolo Lazzari et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Cannabinoid CB2 receptors are involved in the regulation of fibrogenesis during skin wound repair in mice

(2016) SHAN-SHAN LI et al.   Molecular Medicine Reports

The novel cannabinoid antagonist SM-11 reduces hedonic aspect of food intake through a dopamine-dependent mechanism

(2016) G.R. Fois et al.   PHARMACOLOGICAL RESEARCH

Interaction between NMDA and CB2 function in the dorsal hippocampus on memory consolidation impairment: an isobologram analysis

(2016) Mohammad Nasehi et al.   PSYCHOPHARMACOLOGY

Selective, Nontoxic CB2 Cannabinoid o-Quinone with in Vivo Activity against Triple-Negative Breast Cancer

(2015) Paula Morales et al.   JOURNAL OF MEDICINAL CHEMISTRY

Tricyclic pyrazoles part 7. Discovery of potent and selective dihydrothienocyclopentapyrazole derived CB2 ligands

(2014) Giansalvo Pinna et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: A versatile architecture for CB2 selective ligands

(2014) Giovanni Pinna et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

An Effective Prodrug Strategy to Selectively Enhance Ocular Exposure of a Cannabinoid Receptor (CB1/2) Agonist

(2013) Nello Mainolfi et al.   JOURNAL OF MEDICINAL CHEMISTRY

Therapeutic Utility of Cannabinoid Receptor Type 2 (CB2) Selective Agonists

(2013) Sangdon Han et al.   JOURNAL OF MEDICINAL CHEMISTRY

The Importance of Hydrogen Bonding and Aromatic Stacking to the Affinity and Efficacy of Cannabinoid Receptor CB2 Antagonist, 5-(4-chloro-3-methylphenyl)-1-[(4-methylphenyl)methyl]-N-[(1S,2S,4R)-1,3,3-trimethylbicyclo[2.2.1]hept-2-yl]-1H-pyrazole-3-carboxamide (SR144528)

(2013) Evangelia Kotsikorou et al.   JOURNAL OF MEDICINAL CHEMISTRY

Discovery of 1-(2,4-Dichlorophenyl)-N-(piperidin-1-yl)-4-((pyrrolidine-1-sulfonamido)methyl)-5-(5-((4-(trifluoromethyl)phenyl)ethynyl)thiophene-2-yl)-1H-pyrazole-3-carboxamide as a Novel Peripherally Restricted Cannabinoid-1 Receptor Antagonist with Significant Weight-Loss Efficacy in Diet-Induced Obese Mice

(2013) Chun-Ping Chang et al.   JOURNAL OF MEDICINAL CHEMISTRY

Novel Triaryl Sulfonamide Derivatives as Selective Cannabinoid Receptor 2 Inverse Agonists and Osteoclast Inhibitors: Discovery, Optimization, and Biological Evaluation

(2013) Peng Yang et al.   JOURNAL OF MEDICINAL CHEMISTRY

NESS06SM reduces body weight with an improved profile relative to SR141716A

(2013) Andrea Mastinu et al.   PHARMACOLOGICAL RESEARCH

NESS038C6, a novel selective CB1 antagonist agent with anti-obesity activity and improved molecular profile

(2012) Andrea Mastinu et al.   BEHAVIOURAL BRAIN RESEARCH

Neutral antagonism at the cannabinoid 1 receptor: a safer treatment for obesity

(2012) F J Meye et al.   MOLECULAR PSYCHIATRY

Emerging strategies for exploiting cannabinoid receptor agonists as medicines

(2009) Roger G Pertwee   BRITISH JOURNAL OF PHARMACOLOGY

1-(2′,4′-dichlorophenyl)-6-methyl-N-cyclohexylamine-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide, a novel CB2 agonist, alleviates neuropathic pain through functional microglial changes in mice

(2009) L. Luongo et al.   NEUROBIOLOGY OF DISEASE

Conformationally Constrained Analogues ofN-(Piperidinyl)-5-(4-Chlorophenyl)-1-(2,4- Dichlorophenyl)-4-Methyl-1H-Pyrazole-3-Carboxamide (SR141716): Design, Synthesis, Computational Analysis, And Biological Evaluations

(2008) Yanan Zhang et al.   JOURNAL OF MEDICINAL CHEMISTRY

End of the line for cannabinoid receptor 1 as an anti-obesity target?

(2008) Dan Jones   NATURE REVIEWS DRUG DISCOVERY

Endocannabinoids in the retina: From marijuana to neuroprotection

(2008) Stephen Yazulla   PROGRESS IN RETINAL AND EYE RESEARCH